home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.40 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

32 33 Next >

Viking Therapeutics Inc. (NASDAQ: VKTX) Near Top of Volume Charts in Tuesday Trading

February 27, 2024

Via Investor Brand Network

Weight Loss Drug Market Gets Crowded As Viking Therapeutics Drops Encouraging Phase 2 Data From Obesity Study ↗

February 27, 2024

Viking Therapeutics' VK2735, a dual GLP-1 and GIP receptor agonist, achieved significant weight loss (up to 14.7%) in metabolic disorder patients. Safe, well-tolerated treatment with no observed...

Via Benzinga

Nasdaq Rises 50 Points; Lowe's Earnings Top Views ↗

February 27, 2024

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose...

Via Benzinga

Topics Stocks

Why Is Viking Therapeutics (VKTX) Stock Up 96% Today? ↗

February 27, 2024

Viking Therapeutics stock is up on Tuesday with heavy trading of VKTX shares after the company reported positive Phase 2 trial results!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 27, 2024

Via Benzinga

(VKTX) - Analyzing Viking Therapeutics's Short Interest ↗

February 20, 2024

Via Benzinga

Recap: Viking Therapeutics Q4 Earnings ↗

February 07, 2024

Via Benzinga

Earnings Scheduled For February 7, 2024 ↗

February 07, 2024

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.

Via Benzinga

Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results ↗

February 27, 2024

Eli Lilly and Novo Nordisk fell modestly.

Via Investor's Business Daily

Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗

February 26, 2024

The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.

Via Investor's Business Daily

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗

February 22, 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

February 19, 2024

Via Benzinga

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

Earnings Preview: Viking Therapeutics ↗

February 06, 2024

Via Benzinga

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution ↗

February 14, 2024

Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.

Via InvestorPlace

Amazon, Progress Software And 2 Other Stocks Insiders Are Selling ↗

February 12, 2024

The Nasdaq 100 closed higher by 1% on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug ↗

February 08, 2024

The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss.

Via Investor's Business Daily

Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday ↗

February 08, 2024

U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday.

Via Benzinga

Topics Stocks

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 08, 2024

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.

Via Benzinga

The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 ↗

February 02, 2024

These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns

Via InvestorPlace

2 Rising Biotechs That Could Become the Next Novo Nordisk ↗

January 29, 2024

Each of these companies has a big market in its sights.

Via The Motley Fool

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 ↗

January 22, 2024

Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.

Via InvestorPlace

2 Stocks That Could Soar This Year: Are They Buys? ↗

January 22, 2024

They might perform well in 2024, but how will they do beyond that?

Via The Motley Fool

2 biotechs with promising weight-loss drugs coming

January 16, 2024

Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.

Via MarketBeat

The 3 Best Biotech Stocks to Buy in January 2024 ↗

January 09, 2024

Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

January 09, 2024

Via Benzinga

M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024 ↗

January 02, 2024

Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024.

Via InvestorPlace

Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics? ↗

December 12, 2023

Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.

Via The Motley Fool

Why Viking Therapeutics Was Crushing It This Week ↗

December 08, 2023

Nowadays, it's good to be a developer of next-generation weight loss drugs.

Via The Motley Fool

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com